Influenza vaccines are considered as an optimum source of prevention from diseases caused by flu virus. Since the H1N1 pandemic, worldwide authorities have started taking a proactive approach in the vaccination process. Virus of previous pandemics are still present in the environment, and in the coming future, they may be classified as strains to be updated in seasonal vaccines.
Moreover, a large chunk of global population is affected by influenza-related problems. In such a scenario, a huge opportunity lies for the industry participants to tap the fast growing market.
In 2010, the global market for seasonal influenza vaccines was estimated to have reached worth US$ 3.8 Billion backed by certain key prominent factors. With the arrival of new technologies and manufacturers, the market will further witness a remarkable growth in the years to come. Moreover, the approval of new seasonal influenza vaccines by authorities, and significant developments in the adjuvant technology are going to impact the market in a positive manner.
Emerging markets are the centre of focus in the global seasonal influenza vaccine market landscape. A vast population as a target group and significantly low vaccination coverage are the prominent factors which will drive the future growth in countries, such as China and India. Market players have already started devising strategies, including signing of agreements with domestic manufacturers and distributors, to increase their presence in China. India, on the other hand, is engaged in the collection of data which may facilitate the development of flu vaccination strategies among the population.
Our report “Global Influenza Vaccine Market Analysis” presents a distinguished insight into the global market for influenza vaccines in a manner that it analyzes almost all the associated key aspects and new developments. The report comprehensively covers important trends in key countries of the world with respect to influenza vaccination, and delves into the future impact. Moreover, the future outlook till 2013 has also been presented for areas, such as market, vaccine brands and production. Last but not the least, the report also includes company profiling which will assist clients in gaining knowledge regarding private sector participation. Overall, the report will prove as an important source of knowledge and statistics for clients and investors.
